QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, May 30, 2007, 27(22):5895-5902; doi:10.1523/JNEUROSCI.5260-06.2007

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Hatzipetros, T. Articles by Yamamoto, B. K. Search for Related Content PubMed PubMed Citation Articles by Hatzipetros, T. Articles by Yamamoto, B. K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB d-METHAMPHETAMINE GLUTAMIC ACID HYDROCHLORIDE HALOPERIDOL Medline Plus Health Information Methamphetamine

 Previous Article  |  Next Article 

Behavioral/Systems/Cognitive
Haloperidol Treatment after High-Dose Methamphetamine Administration Is Excitotoxic to GABA Cells in the Substantia Nigra Pars Reticulata

Theo Hatzipetros,¹ Jamie G. Raudensky,¹ Jean-Jacques Soghomonian,² and Bryan K. Yamamoto¹

¹Laboratory of Neurochemistry, Department of Pharmacology and Experimental Therapeutics and ²Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, Massachusetts 02118

Correspondence should be addressed to Bryan K. Yamamoto, Department of Pharmacology, Boston University School of Medicine, 715 Albany Street, L-613, Boston, MA 02118. Email: bkyam{at}bu.edu

The therapeutic management of methamphetamine (METH)-induced psychoses often involves treatment with the typical antipsychotic drug and dopamine D₂ receptor antagonist haloperidol. We report here that subchronic haloperidol administration after a high-dose regimen of METH produces a heretofore unrecognized toxicity to GABAergic cells, as reflected by GAD67 mRNA expression histochemistry, in the rat substantia nigra pars reticulata (SNr) through an acute and persistent augmentation of glutamate release, NMDA receptor activation, and DNA fragmentation. The dopaminergic cells in the substantia nigra pars compacta were unaffected by METH or haloperidol alone or the combination of METH and haloperidol. These findings suggest that the current therapeutic management of METH-induced psychoses with haloperidol may be contraindicated because of a resultant GABAergic cell death in the SNr, which may predispose some individuals to the development of hyperkinetic movement disorders and seizures.

Key words: antipsychotics; glutamate; dopamine; microdialysis; basal ganglia; neurodegeneration

---

Received Dec. 5, 2006; revised April 16, 2007; accepted April 17, 2007.

Correspondence should be addressed to Bryan K. Yamamoto, Department of Pharmacology, Boston University School of Medicine, 715 Albany Street, L-613, Boston, MA 02118. Email: bkyam{at}bu.edu

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help